Skip to main content
. 2022 Feb 15;12(2):816–828.

Figure 3.

Figure 3

SNHG15 decreased cisplatin-induced apoptosis and ROS levels in osteosarcoma cells. (A) SNHG15 was overexpressed in U2OS and 143B cells and assessed using RT-PCR. (B-G) U2OS and 143B cells with or without SNHG15 overexpression were treated with cisplatin. Cell apoptosis and cell viability were analyzed using Western blot (B and D), CCK-8 (C and E) and flow cytometry assays (F and G). The relative expression of cleaved PARP to GAPDH was quantified in (B and D). Data in (C, E and G) are presented as the means ± SD of triplicate measurements, **P<0.01 and ***P<0.001. (H) SNHG15 was silenced in U2OS cells using siRNAs, and its expression was analyzed using RT-PCR. (I-K) Cell apoptosis was analyzed using flow cytometry (I, J) and Western blot analysis (K). (L, M) ROS levels were analyzed using flow cytometry. Data in M are presented as the means ± SD of triplicate measurements, **P<0.01 and ***P<0.001. (N) p53 expression was silenced in U2OS cells with or without SNHG15 knockdown, and then the cells were treated with cisplatin. Cell apoptosis was detected using Western blotting.